Media coverage about Kite Pharma (NASDAQ:KITE) has trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.9866672594196 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s scoring:
- Short Interest in Kite Pharma, Inc. (KITE) Drops By 32.7% (americanbankingnews.com)
- Gilead to Acquire Kite Pharma for $11.9 Billion (jdsupra.com)
- Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move. – Motley Fool (fool.com)
- Implied Volatility Surging for Kite Pharma (KITE) Stock Options – Nasdaq (nasdaq.com)
KITE has been the topic of several recent research reports. Canaccord Genuity set a $90.00 price target on Kite Pharma and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Vetr lowered Kite Pharma from a “buy” rating to a “hold” rating and set a $116.82 price target on the stock. in a research report on Monday, August 7th. Cowen and Company reissued a “buy” rating on shares of Kite Pharma in a research report on Wednesday, June 7th. FBR & Co reissued a “buy” rating on shares of Kite Pharma in a research report on Tuesday, May 30th. Finally, Wedbush reissued an “underperform” rating and set a $54.00 price target on shares of Kite Pharma in a research report on Friday, June 16th. Fifteen research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Kite Pharma currently has an average rating of “Hold” and a consensus price target of $91.10.
Kite Pharma (KITE) opened at 178.61 on Monday. The company’s market cap is $10.21 billion. Kite Pharma has a 1-year low of $39.82 and a 1-year high of $179.69. The stock has a 50 day moving average price of $144.96 and a 200 day moving average price of $100.11.
Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.97) by $0.03. The firm had revenue of $10.10 million during the quarter, compared to the consensus estimate of $9.59 million. Kite Pharma had a negative return on equity of 59.56% and a negative net margin of 1,117.44%. The business’s revenue for the quarter was up 110.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.91) EPS. Equities analysts forecast that Kite Pharma will post ($8.23) earnings per share for the current year.
In related news, Director Owen N. Witte sold 25,000 shares of Kite Pharma stock in a transaction on Monday, June 26th. The stock was sold at an average price of $100.30, for a total transaction of $2,507,500.00. Following the completion of the sale, the director now directly owns 98,750 shares of the company’s stock, valued at $9,904,625. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Helen Susan Kim sold 6,251 shares of Kite Pharma stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $120.09, for a total value of $750,682.59. Following the sale, the executive vice president now directly owns 22,259 shares of the company’s stock, valued at $2,673,083.31. The disclosure for this sale can be found here. Insiders sold a total of 200,849 shares of company stock valued at $22,586,128 over the last three months. Insiders own 14.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Kite Pharma (KITE) Earns Daily Coverage Optimism Rating of 0.13” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2017/09/18/kite-pharma-kite-earns-daily-coverage-optimism-rating-of-0-13.html.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.